Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

克拉斯 西妥昔单抗 神经母细胞瘤RAS病毒癌基因同源物 医学 结直肠癌 肿瘤科 帕尼单抗 内科学 癌症研究 癌症 化疗
作者
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent‐Puig,Frederique Madeleine Penault-Llorca,Philippe R Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:11 (8): 753-762 被引量:2144
标识
DOI:10.1016/s1470-2045(10)70130-3
摘要

Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic colorectal cancer are now profiled for seven KRAS mutations before receiving cetuximab or panitumumab. However, most patients with KRAS wild-type tumours still do not respond. We studied the effect of other downstream mutations on the efficacy of cetuximab in, to our knowledge, the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era.1022 tumour DNA samples (73 from fresh-frozen and 949 from formalin-fixed, paraffin-embedded tissue) from patients treated with cetuximab between 2001 and 2008 were gathered from 11 centres in seven European countries. 773 primary tumour samples had sufficient quality DNA and were included in mutation frequency analyses; mass spectrometry genotyping of tumour samples for KRAS, BRAF, NRAS, and PIK3CA was done centrally. We analysed objective response, progression-free survival (PFS), and overall survival in molecularly defined subgroups of the 649 chemotherapy-refractory patients treated with cetuximab plus chemotherapy.40.0% (299/747) of the tumours harboured a KRAS mutation, 14.5% (108/743) harboured a PIK3CA mutation (of which 68.5% [74/108] were located in exon 9 and 20.4% [22/108] in exon 20), 4.7% (36/761) harboured a BRAF mutation, and 2.6% (17/644) harboured an NRAS mutation. KRAS mutants did not derive benefit compared with wild types, with a response rate of 6.7% (17/253) versus 35.8% (126/352; odds ratio [OR] 0.13, 95% CI 0.07-0.22; p<0.0001), a median PFS of 12 weeks versus 24 weeks (hazard ratio [HR] 1.98, 1.66-2.36; p<0.0001), and a median overall survival of 32 weeks versus 50 weeks (1.75, 1.47-2.09; p<0.0001). In KRAS wild types, carriers of BRAF and NRAS mutations had a significantly lower response rate than did BRAF and NRAS wild types, with a response rate of 8.3% (2/24) in carriers of BRAF mutations versus 38.0% in BRAF wild types (124/326; OR 0.15, 95% CI 0.02-0.51; p=0.0012); and 7.7% (1/13) in carriers of NRAS mutations versus 38.1% in NRAS wild types (110/289; OR 0.14, 0.007-0.70; p=0.013). PIK3CA exon 9 mutations had no effect, whereas exon 20 mutations were associated with a worse outcome compared with wild types, with a response rate of 0.0% (0/9) versus 36.8% (121/329; OR 0.00, 0.00-0.89; p=0.029), a median PFS of 11.5 weeks versus 24 weeks (HR 2.52, 1.33-4.78; p=0.013), and a median overall survival of 34 weeks versus 51 weeks (3.29, 1.60-6.74; p=0.0057). Multivariate analysis and conditional inference trees confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA exon 20 mutations (in that order) gives additional information about outcome. Objective response rates in our series were 24.4% in the unselected population, 36.3% in the KRAS wild-type selected population, and 41.2% in the KRAS, BRAF, NRAS, and PIK3CA exon 20 wild-type population.While confirming the negative effect of KRAS mutations on outcome after cetuximab, we show that BRAF, NRAS, and PIK3CA exon 20 mutations are significantly associated with a low response rate. Objective response rates could be improved by additional genotyping of BRAF, NRAS, and PIK3CA exon 20 mutations in a KRAS wild-type population.Belgian Federation against Cancer (Stichting tegen Kanker).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ines完成签到 ,获得积分10
刚刚
陈琛琛发布了新的文献求助10
2秒前
howeVer完成签到 ,获得积分10
2秒前
酷波er的应助被西梅采纳,获得10
2秒前
小瞎鱼发布了新的文献求助10
3秒前
TUTU完成签到 ,获得积分10
3秒前
Sothnia发布了新的文献求助20
3秒前
赵迎杰完成签到,获得积分10
3秒前
冷艳的紫安完成签到,获得积分10
6秒前
6秒前
6秒前
墙强联手发布了新的文献求助10
7秒前
7秒前
8秒前
卿卿完成签到,获得积分10
9秒前
11秒前
梦时轩完成签到,获得积分10
12秒前
hype发布了新的文献求助10
12秒前
伊莎贝儿发布了新的文献求助10
12秒前
平常迎天的应助被路口采纳,获得30
12秒前
科研通AI6.4的应助被路口采纳,获得10
12秒前
whj发布了新的文献求助10
12秒前
威武的QQ完成签到,获得积分10
13秒前
麦田捕手发布了新的文献求助10
13秒前
pokexuejiao发布了新的文献求助30
13秒前
13秒前
Lost_Flight完成签到,获得积分10
13秒前
笨笨吐司完成签到 ,获得积分10
14秒前
FashionBoy的应助被夹心巧克力采纳,获得10
15秒前
乐乐的应助被田宇飞采纳,获得30
15秒前
16秒前
风中琦完成签到 ,获得积分10
16秒前
赘婿的应助被布蕾翠翠奶芙采纳,获得10
16秒前
huahuahua发布了新的文献求助10
16秒前
ZongchenYang完成签到,获得积分10
17秒前
东邪西毒加任我行完成签到,获得积分10
18秒前
18秒前
312完成签到 ,获得积分10
20秒前
水墨丹青完成签到 ,获得积分10
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190845
求助须知:如何正确求助?哪些是违规求助? 9577920
关于积分的说明 21855571
捐赠科研通 7789983
什么是DOI,文献DOI怎么找? 3436475
关于科研通互助平台的介绍 2560308
邀请新用户注册赠送积分活动 2483197